SI2368999T1 - Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe - Google Patents

Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Info

Publication number
SI2368999T1
SI2368999T1 SI200831200T SI200831200T SI2368999T1 SI 2368999 T1 SI2368999 T1 SI 2368999T1 SI 200831200 T SI200831200 T SI 200831200T SI 200831200 T SI200831200 T SI 200831200T SI 2368999 T1 SI2368999 T1 SI 2368999T1
Authority
SI
Slovenia
Prior art keywords
amino acid
alkaline phosphatase
kits
methods
bone targeted
Prior art date
Application number
SI200831200T
Other languages
English (en)
Slovenian (sl)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Original Assignee
Alexion Pharma Holding,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Holding, filed Critical Alexion Pharma Holding,
Publication of SI2368999T1 publication Critical patent/SI2368999T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
SI200831200T 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe SI2368999T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
EP11004496.3A EP2368999B1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
SI2368999T1 true SI2368999T1 (sl) 2014-07-31

Family

ID=40001639

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831780A SI2662448T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe
SI200831200T SI2368999T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200831780A SI2662448T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Country Status (25)

Country Link
US (1) US20100297119A1 (enExample)
EP (3) EP2158319B1 (enExample)
JP (1) JP5732603B2 (enExample)
AT (1) ATE536413T1 (enExample)
AU (1) AU2008250945B2 (enExample)
BR (2) BR122019000505B1 (enExample)
CA (1) CA2687001C (enExample)
CY (1) CY2016005I2 (enExample)
DE (1) DE202008018131U1 (enExample)
DK (3) DK2158319T3 (enExample)
ES (3) ES2380546T3 (enExample)
FR (1) FR16C0007I2 (enExample)
HR (1) HRP20140416T1 (enExample)
HU (2) HUE031655T2 (enExample)
IL (1) IL202057A0 (enExample)
LT (1) LTC2368999I2 (enExample)
LU (1) LU92976I2 (enExample)
ME (1) ME01828B (enExample)
NL (1) NL300798I1 (enExample)
NO (1) NO2016002I1 (enExample)
PL (3) PL2662448T3 (enExample)
PT (3) PT2662448T (enExample)
RS (1) RS53302B (enExample)
SI (2) SI2662448T1 (enExample)
WO (1) WO2008138131A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
WO2008151088A2 (en) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
EP2598533B1 (en) 2010-07-28 2019-02-20 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2013058833A1 (en) * 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
CN106164262B (zh) * 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) * 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
KR102644116B1 (ko) * 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019726A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2017367699B2 (en) * 2016-11-30 2023-12-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
KR20190093186A (ko) 2016-12-09 2019-08-08 글리크닉 인코포레이티드 다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
PE20191354A1 (es) 2016-12-09 2019-10-01 Gliknik Inc Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
JP7142021B2 (ja) * 2017-03-09 2022-09-26 アレクシオン ファーマシューティカルズ, インコーポレイテッド 糖タンパク質製造プロセス
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ, インコーポレイテッド 成人及び青年における低ホスファターゼ症(hpp)を治療する方法
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
JP2023504208A (ja) * 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
CA3190513A1 (en) * 2020-09-03 2022-03-10 Jeffrey S. Bartlett Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US12083169B2 (en) * 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
DE60233047D1 (de) 2001-05-14 2009-09-03 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
PL2348114T3 (pl) * 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
MXPA06014972A (es) 2004-06-23 2007-03-07 Genzyme Corp Metodos y composiciones para el tratamiento de enfermedades poliquisticas.
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Also Published As

Publication number Publication date
BRPI0811198A2 (pt) 2014-10-21
PT2368999E (pt) 2014-05-26
PT2662448T (pt) 2017-03-29
AU2008250945A2 (en) 2009-12-24
RS53302B (sr) 2014-08-29
DK2158319T3 (da) 2012-03-19
HK1141047A1 (en) 2010-10-29
HK1191372A1 (en) 2014-07-25
WO2008138131A4 (en) 2008-12-31
HK1162589A1 (en) 2012-08-31
LU92976I2 (en) 2016-04-11
WO2008138131A1 (en) 2008-11-20
CY2016005I1 (el) 2016-08-31
BR122019000505A2 (pt) 2021-12-14
BRPI0811198A8 (pt) 2018-08-14
HRP20140416T1 (hr) 2014-06-20
EP2158319B1 (en) 2011-12-07
IL202057A0 (en) 2011-08-01
AU2008250945A1 (en) 2008-11-20
EP2158319A1 (en) 2010-03-03
PL2368999T3 (pl) 2014-08-29
AU2008250945B2 (en) 2013-12-12
NO2016002I2 (no) 2016-02-02
ATE536413T1 (de) 2011-12-15
SI2662448T1 (sl) 2017-05-31
BR122019000505B1 (pt) 2022-01-18
BRPI0811198B8 (pt) 2021-05-25
LTC2368999I2 (lt) 2017-09-25
ES2471915T3 (es) 2014-06-27
BRPI0811198B1 (pt) 2021-03-09
JP2010526543A (ja) 2010-08-05
EP2662448B1 (en) 2016-12-21
EP2368999A1 (en) 2011-09-28
FR16C0007I1 (enExample) 2016-04-15
NL300798I2 (enExample) 2016-03-16
US20100297119A1 (en) 2010-11-25
CA2687001C (en) 2019-02-12
EP2158319A4 (en) 2010-07-21
PL2158319T3 (pl) 2012-05-31
PL2662448T3 (pl) 2017-07-31
CA2687001A1 (en) 2008-11-20
ES2380546T3 (es) 2012-05-16
ME01828B (me) 2014-12-20
PT2158319E (pt) 2012-03-06
DK2662448T3 (en) 2017-03-20
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
WO2008138131A9 (en) 2009-08-06
EP2368999B1 (en) 2014-03-12
ES2619332T3 (es) 2017-06-26
PL2158319T4 (pl) 2016-04-29
NO2016002I1 (no) 2016-02-02
HUS1600005I1 (hu) 2016-02-29
DK2368999T3 (da) 2014-05-26
NL300798I1 (enExample) 2016-03-16
CY2016005I2 (el) 2016-08-31
FR16C0007I2 (fr) 2017-01-27
DE202008018131U1 (de) 2011-12-30
JP5732603B2 (ja) 2015-06-10
LTPA2016004I1 (lt) 2016-02-25

Similar Documents

Publication Publication Date Title
NL300798I1 (enExample)
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
BRPI0414598A (pt) indóis substituìdos
HRP20090245T1 (en) Pyy agonists and uses thereof
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
MX347545B (es) Polipeptidos con actividad xilanasa.
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
TW200630367A (en) Substituted adenines and the uses thereof
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
DK2084198T3 (da) Beklædningssammensætning
EP2004352A4 (en) AMINO ACID SUPPLEMENT FOR PEPTIDE CONSTRUCTIONS
ES2573462T3 (es) Polipéptidos de PH20 soluble extendida y usos de los mismos
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
MY150639A (en) T cell adhesion molecule and antibody thereto
TW200731985A (en) A composition for wound healing and use thereof
UA43602U (ru) Применение производных 1,2,3-триазол(1н) -4-карбоновых кислот как ноотропных средств